세계의 편두통 치료제 시장 보고서(2025년)

Migraine Drugs Global Market Report 2025

US $ 4,490 ￦ 6,156,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,898,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,640,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

편두통 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 5.8%의 연평균 성장률(CAGR)로 72억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 맞춤형 의료 접근법, 원격의료 및 원격진료, 의료 정책 및 보험 적용, 전 세계 편두통 부담 증가, 병용요법 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 표적 치료, 원격의료 및 원격진료, 환자 중심 접근법, 디지털 치료, 편두통 치료의 바이오시밀러, 임상 연구 및 임상시험 등이 있습니다.

편두통 치료제 시장의 예상 성장은 여성 인구의 증가에 의해 촉진될 것으로 예상됩니다. 특정 기간 동안 각 국가 및 지역의 모든 연령대의 여성을 포함한 여성 인구는 편두통 치료제 수요를 촉진하는 데 중요한 역할을 하고 있습니다. 편두통의 유병률은 남성에 비해 여성에서 현저하게 높으며, 유전적, 호르몬적, 환경적 요인이 복합적으로 작용합니다. UN이 발표한 World Population Prospects 2022에 따르면 2022년 현재 세계 여성 인구는 40억 명으로 추정되며, 세계 인구의 49.75%를 차지합니다. 예측에 따르면, 2049년에는 여성 인구가 남성 인구를 넘어설 것으로 보입니다. 결과적으로 여성 인구의 증가는 편두통 치료제 시장 성장의 중요한 촉진제가 되고 있습니다.

편두통의 유병률 증가는 향후 몇 년 동안 편두통 치료제 시장의 성장에 더욱 기여할 것으로 예상됩니다. 편두통은 뇌의 한쪽이 맥박이 뛰는 듯한 두근거리는 통증이 반복적으로 발생하는 것이 특징이며, 편두통의 유병률이 증가함에 따라 효과적인 편두통 치료제에 대한 수요가 증가하고 있습니다. 이러한 급격한 증가는 제약회사가 확대되는 환자군의 요구에 대응하는 치료법을 개발 및 제공함으로써 기술 혁신과 매출 성장을 촉진합니다. 예를 들어, 호주 재무부가 2023년 3월 발표한 'Migraine Australia 2022-23 Pre-Budget Submissions'(편두통 호주 2022-23년 예산안 제출 전 예산안)에 따르면, 호주는 전 세계적으로 편두통 유병률이 가장 높은 국가 중 하나입니다. 편두통 유병률이 가장 높은 국가 중 하나이며(28%), 4명 중 1명이 편두통에 시달리고 있습니다. 이 유병률은 제2형 당뇨병, 간질, 천식을 합친 것보다 높습니다. 따라서 편두통 유병률의 증가는 편두통 치료제 시장의 성장에 중요한 촉진제가 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 편두통 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
• 최종 이용 산업 분석
• 세계의 편두통 치료제 시장 : 성장률 분석
• 세계의 편두통 치료제 시장 실적 : 규모와 성장, 2019-2024
• 세계의 편두통 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 편두통 치료제 전체 시장(TAM)

제6장 시장 세분화

• 세계의 편두통 치료제 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 트립탄
• 베타 차단제
• 안지오텐신 차단제
• 삼환계 항우울제
• 항경련제
• 세계의 편두통 치료제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 주사 가능
• 기타 루트
• 세계의 편두통 치료제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원과 진료소
• 소매 약국
• 온라인 약국
• 기타 최종사용자
• 세계의 편두통 치료제 시장, 트립탄 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• Sumatriptan
• Rizatriptan
• Zolmitriptan
• Eletriptan
• 세계의 편두통 치료제 시장, 베타 차단제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• Propranolol
• Metoprolol
• Timolol
• 세계의 편두통 치료제 시장 안지오텐신 차단제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• Candesartan
• Losartan
• 세계의 편두통 치료제 시장, 삼환계 화합물 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• Amitriptyline
• Nortriptyline
• 세계의 편두통 치료제 시장, 항경련제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• Topiramate
• Valproate

제7장 지역별·국가별 분석

• 세계의 편두통 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 편두통 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 편두통 치료제 시장 : 경쟁 구도
• 편두통 치료제 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• AbbVie Inc.
• Sanofi SA
• Novartis AG
• AstraZeneca
• Abbott Laboratories
• GlaxoSmithKline plc.
• Eli Lilly and Company
• Amgen Inc.
• Otsuka Holdings Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• Eisai Co. Ltd.
• Dr Reddys Laboratories Ltd.
• H. Lundbeck A/S
• Amneal Pharmaceuticals Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 편두통 치료제 시장 2029 : 새로운 기회를 제공하는 국가
• 편두통 치료제 시장 2029 : 새로운 기회를 제공하는 부문
• 편두통 치료제 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Migraine drugs are medications designed to address a neurological condition characterized by intense, throbbing headaches. These drugs operate by targeting various physiological mechanisms responsible for causing migraines.

The primary classes of migraine drugs include triptans, beta-blockers, angiotensin blockers, tricyclics, and anticonvulsants. Triptans, for example, work by altering blood circulation in the brain and modulating how the brain processes pain signals. These drugs can be administered through various routes, such as oral or injectable, and are utilized by diverse end-users, including hospitals and clinics, retail pharmacies, online pharmacies, and others.

The migraine drugs market research report is one of a series of new reports from The Business Research Company that provides migraine drugs market statistics, including migraine drugs industry global market size, regional shares, competitors with a migraine drugs market share, detailed migraine drugs market segments, market trends and opportunities, and any further data you may need to thrive in the migraine drugs industry. This migraine drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The migraine drugs market size has grown strongly in recent years. It will grow from $5.38 billion in 2024 to $5.77 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to advancements in drug formulations, increased awareness and diagnosis, stress and lifestyle factors, expansion of generic drugs, emergence of cgrp inhibitors.

The migraine drugs market size is expected to see strong growth in the next few years. It will grow to $7.22 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to personalized medicine approaches, telemedicine and remote consultations, healthcare policy and insurance coverage, increasing global migraine burden, combination therapies. Major trends in the forecast period include targeted therapies, telemedicine and remote consultations, patient-centric approaches, digital therapeutics, biosimilars in migraine treatment, clinical research and trials.

The anticipated growth of the migraine drugs market is expected to be propelled by the increasing female population. The female population, encompassing females across all age groups in each country or region during a specific period, plays a crucial role in driving the demand for migraine medications. The prevalence of migraines is notably higher in the female population compared to males, influenced by a combination of genetic, hormonal, and environmental factors. As of 2022, according to the World Population Prospects 2022 released by the United Nations, the global female population is estimated at 4.00 billion, constituting 49.75% of the world population. Projections suggest that females will outnumber males by the year 2049. Consequently, the expanding female population serves as a key driver behind the growth of the migraine drugs market.

The increase in the prevalence of migraines is expected to further contribute to the growth of the migraine drug market in the coming years. Migraine headaches, characterized by recurring episodes of pulsing and pounding pain on one side of the brain, have become more prevalent, leading to a rising demand for effective migraine medications. This surge in prevalence fuels innovation and sales growth as pharmaceutical companies develop and provide therapies to address the needs of an expanding patient population. For instance, as reported in March 2023 by the Migraine Australia 2022-23 Pre-Budget Submissions, a document released by the Australian Treasury, Australia has one of the highest migraine rates globally (28%), affecting one in every four people. This prevalence surpasses that of type 2 diabetes, epilepsy, and asthma combined. Therefore, the increasing prevalence of migraines stands as a significant driver for the growth of the migraine drug market.

Major companies operating in the migraine drugs market are concentrating on the development of innovative products to enhance patient care and gain a competitive advantage. One such example is Zavzpret, a nasal spray medication designed for the acute treatment of migraines with or without aura in adults. For example, in March 2023, Pfizer, a US-based pharmaceutical company, obtained approval from the Food and Drug Administration (FDA) for Zavzpret. It is the first and only approved zavegepant (CGRP receptor antagonist) nasal spray for the acute treatment of migraine. Targeting the calcitonin gene-related peptide (CGRP), Zavzpret offers a new treatment option, particularly for individuals experiencing migraines with nausea and vomiting, as well as for those unable to use triptans due to cardiovascular risks.

In May 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired BioHaven Pharmaceutical Holding Company Ltd. for $11.6 billion. Through this acquisition, Pfizer aims to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraines. This strategic move underscores the pharmaceutical industry's commitment to advancing migraine drug development and addressing patient needs.

Major companies operating in the migraine drugs market report are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Merck & Co. Inc., AbbVie Inc., AbbVie Inc., Sanofi SA, Novartis AG, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Dr Reddy's Laboratories Ltd., H. Lundbeck A/S, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Neurelis Inc., ALDER BIOPHARMACEUTICALS INC., eNeura Inc., Winston Pharmaceuticals Ltd.

North America was the largest region in the migraine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the migraine drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the migraine drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The migraine drugs market consists of sales of analgesics, ergotamines, sumatriptan, and rizatriptan. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Migraine Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on migraine drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for migraine drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The migraine drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Triptans; Betablockers; Angiotensin Blockers; Tricyclics; Anticonvulsants
• 2) By Route of Administration: Oral; Injectable; Other Routes
• 3) By End-User: Hospitals And Clinics; Retail Pharmacy; Online Pharmacy; Other End Users
• Subsegments:
• 1) By Triptans: Sumatriptan; Rizatriptan; Zolmitriptan; Eletriptan
• 2) By Beta Blockers: Propranolol; Metoprolol; Timolol
• 3) By Angiotensin Blockers: Candesartan; Losartan
• 4) By Tricyclics: Amitriptyline; Nortriptyline
• 5) By Anticonvulsants: Topiramate; Valproate
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Bayer AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Migraine Drugs Market Characteristics

3. Migraine Drugs Market Trends And Strategies

4. Migraine Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Migraine Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Migraine Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Migraine Drugs Market Growth Rate Analysis
• 5.4. Global Migraine Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Migraine Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Migraine Drugs Total Addressable Market (TAM)

6. Migraine Drugs Market Segmentation

• 6.1. Global Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triptans
• Betablockers
• Angiotensin Blockers
• Tricyclics
• Anticonvulsants
• 6.2. Global Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Routes
• 6.3. Global Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Retail Pharmacy
• Online Pharmacy
• Other End Users
• 6.4. Global Migraine Drugs Market, Sub-Segmentation Of Triptans, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sumatriptan
• Rizatriptan
• Zolmitriptan
• Eletriptan
• 6.5. Global Migraine Drugs Market, Sub-Segmentation Of Beta Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Propranolol
• Metoprolol
• Timolol
• 6.6. Global Migraine Drugs Market, Sub-Segmentation Of Angiotensin Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Candesartan
• Losartan
• 6.7. Global Migraine Drugs Market, Sub-Segmentation Of Tricyclics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amitriptyline
• Nortriptyline
• 6.8. Global Migraine Drugs Market, Sub-Segmentation Of Anticonvulsants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topiramate
• Valproate

7. Migraine Drugs Market Regional And Country Analysis

• 7.1. Global Migraine Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Migraine Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Migraine Drugs Market

• 8.1. Asia-Pacific Migraine Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Migraine Drugs Market

• 9.1. China Migraine Drugs Market Overview
• 9.2. China Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Migraine Drugs Market

• 10.1. India Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Migraine Drugs Market

• 11.1. Japan Migraine Drugs Market Overview
• 11.2. Japan Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Migraine Drugs Market

• 12.1. Australia Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Migraine Drugs Market

• 13.1. Indonesia Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Migraine Drugs Market

• 14.1. South Korea Migraine Drugs Market Overview
• 14.2. South Korea Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Migraine Drugs Market

• 15.1. Western Europe Migraine Drugs Market Overview
• 15.2. Western Europe Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Migraine Drugs Market

• 16.1. UK Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Migraine Drugs Market

• 17.1. Germany Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Migraine Drugs Market

• 18.1. France Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Migraine Drugs Market

• 19.1. Italy Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Migraine Drugs Market

• 20.1. Spain Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Migraine Drugs Market

• 21.1. Eastern Europe Migraine Drugs Market Overview
• 21.2. Eastern Europe Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Migraine Drugs Market

• 22.1. Russia Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Migraine Drugs Market

• 23.1. North America Migraine Drugs Market Overview
• 23.2. North America Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Migraine Drugs Market

• 24.1. USA Migraine Drugs Market Overview
• 24.2. USA Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Migraine Drugs Market

• 25.1. Canada Migraine Drugs Market Overview
• 25.2. Canada Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Migraine Drugs Market

• 26.1. South America Migraine Drugs Market Overview
• 26.2. South America Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Migraine Drugs Market

• 27.1. Brazil Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Migraine Drugs Market

• 28.1. Middle East Migraine Drugs Market Overview
• 28.2. Middle East Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Migraine Drugs Market

• 29.1. Africa Migraine Drugs Market Overview
• 29.2. Africa Migraine Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Migraine Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Migraine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Migraine Drugs Market Competitive Landscape And Company Profiles

• 30.1. Migraine Drugs Market Competitive Landscape
• 30.2. Migraine Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Migraine Drugs Market Other Major And Innovative Companies

• 31.1. AbbVie Inc.
• 31.2. Sanofi SA
• 31.3. Novartis AG
• 31.4. AstraZeneca
• 31.5. Abbott Laboratories
• 31.6. GlaxoSmithKline plc.
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Otsuka Holdings Co. Ltd.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Bausch Health Companies Inc.
• 31.12. Eisai Co. Ltd.
• 31.13. Dr Reddys Laboratories Ltd.
• 31.14. H. Lundbeck A/S
• 31.15. Amneal Pharmaceuticals Inc.

32. Global Migraine Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Migraine Drugs Market

34. Recent Developments In The Migraine Drugs Market

35. Migraine Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Migraine Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Migraine Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Migraine Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료